Cardiac Amyloidosis
74
28
29
14
Key Insights
Highlights
Success Rate
74% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
6.8%
5 terminated out of 74 trials
73.7%
-12.8% vs benchmark
11%
8 trials in Phase 3/4
21%
3 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (74)
Early Detection of Concealed Cardiac Amyloidosis Using AI-ECG and CT-Derived Extracellular Volume in Patients With Atrial Fibrillation
[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy
REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis
PET Imaging Study Using Evuzamitide to Detect Cardiac Amyloidosis in Patients With Inconclusive Nuclear Scans and Elevated TAD1 Levels
Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure
A Study Of Deep Learning For Echo Analysis, Tracking, And Evaluation
AI-based Echocardiography for Detection of Cardiac Amyloidosis
CMR T1 Mapping for Diagnosis of Cardiac Amyloidosis
Test-retest Study With [18F]FBB in Cardiac Amyloidosis
Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis
CHEST-CA: Study of Chest Pain and Hidden Cardiac Amyloidosis
ATTRACT-52: Primary Care Cardiac Amyloidosis Screening in Ordu, Turkey
Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis
Increased Pacemaker Lower Rate in ATTR Cardiac Amyloidosis
Study of Olfactory Disorders in Patients With Cardiac Amyloidosis
Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques
Exploration of Arrhythmia Burden in Cardiac Amyloidosis Using Implantable Loop Recorders
Amylo-Shiatsu-Acute-Chronic: Effects of Shiatsu on Symptoms and Quality of Life of Amyloidosis Patients
Cardiac Amyloidosis Discovery Trial
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis